



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Whole Blood EDTA	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 09:57	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF. INTERVAL	REMARKS
------	---------	------	--------------------------	---------

HAEMOGRAM REPORT

HB AND INDICES

Haemoglobin	L 11.4	G%	12.0 - 15.0
RBC (Electrical Impedance)	H 5.60	millions/cumm	3.80 - 4.80
PCV(Calc)	37.41	%	36.00 - 46.00
MCV (RBC histogram)	L 66.8	fL	83.00 - 101.00
MCH (Calc)	L 20.3	pg	27.00 - 32.00
MCHC (Calc)	L 30.4	gm/dL	31.50 - 34.50
RDW (RBC histogram)	15.40	%	11.00 - 16.00

TOTAL AND DIFFERENTIAL WBC COUNT

Total WBC Count	6390	/μL	4000.00 - 10000.00
Neutrophil	H 73 [%]	%	EXPECTED VALUES 40.00 - 70.00 [Abs] 4665 /μL EXPECTED VALUES 2000.00 - 7000.00
Lymphocyte	L 19	%	20.00 - 40.00 1214 /μL 1000.00 - 3000.00
Eosinophil	02	%	1.00 - 6.00 128 /μL 20.00 - 500.00
Monocytes	06	%	2.00 - 10.00 383 /μL 200.00 - 1000.00
Basophil	00	%	0.00 - 2.00 0 /μL 0.00 - 100.00

PLATELET COUNT

Platelet Count	258000	/μL	150000.00 - 410000.00
MPV	9.20	fL	6.5 - 12
PDW	H 15.5		8 - 13

Method:
 TLC-SF cube technology(Flow Cytometry+ fluorescence),
 DC by microscopy,
 Platelet count by electrical impedance+/-SF cube technology

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
 Consultant Pathologist



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Whole Blood EDTA	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 10:28	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
HAEMATOLOGY INVESTIGATIONS				

ESR <i>Westergren Method</i>	12		mm after 1hr	3 - 20
--	-----------	--	--------------	--------

**BLOOD GROUP AND RH TYPING (Erythrocyte Magnetized Technology)
(Both Forward and Reverse Group)**

ABO Type	AB
Rh Type	POSITIVE

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Page 2 of 9

Printed On : 06-May-2024 17:16



LABORATORY REPORT



Name : **Mrs KALPNABEN B VASAVA** Sex/Age : **Female / 35 Years** Case ID : **40308001493**
 Ref. By : **Mediwheel Full Body Health Checkup** Dis. At : Pt. ID :
 Bill. Loc. : **Health packages** Pt. Loc :

Reg Date and Time : 30-Mar-2024 07:57 Sample Type : **Plasma Fluoride F, Plasma Fluoride PP, Whole Blood EDTA** Mobile No. :
 Sample Date and Time : 30-Mar-2024 07:57 Sample Coll. By : **non** Ref Id1 :
 Report Date and Time : 30-Mar-2024 09:57 Acc. Remarks : Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
Plasma Glucose - F <i>Photometric, Hexokinase</i>	H 104.27	mg/dL	70 - 100	FUS: NIL
Plasma Glucose - PP <i>Photometric, Hexokinase</i>	133.98	mg/dL	70 - 140	PPUS: NIL
Glycated Haemoglobin Estimation				
HbA1C <i>Immunoturbidimetric</i>	5.3	% of total Hb	<5.7: Normal 5.7-6.4: Prediabetes >=6.5: Diabetes	
Estimated Avg Glucose (3 Mths) <i>Calculated</i>	105.41	mg/dL	Not available	

Please Note change in reference range as per ADA 2021 guidelines.

Interpretation :

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.
 Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
 Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
 Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.
 In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.
 The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
 Consultant Pathologist



LABORATORY REPORT



Name : **Mrs KALPNABEN B VASAVA** Sex/Age : **Female / 35 Years** Case ID : **40308001493**
 Ref. By : Mediwheel Full Body Health Checkup Dis. At : Pt. ID :
 Bill. Loc. : Health packages Pt. Loc. :

Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Serum	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 09:57	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
BUN (Blood Urea Nitrogen) <i>GLDH</i>	10.1	mg/dL	7.00 - 18.70	
Uric Acid <i>Uricase-Peroxidase method</i>	5.53	mg/dL	2.6 - 6.2	
Creatinine <i>Jaffe compensated</i>	0.71	mg/dL	0.55 - 1.02	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Page 4 of 9

Printed On : 06-May-2024 17:16



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Serum	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 09:57	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Lipid Profile

Cholesterol <i>Colorimetric, CHOD-POD</i>	162.73	mg/dL	110 - 200	
HDL Cholesterol	46.0	mg/dL	40 - 60	
Triglyceride <i>GPO-POD</i>	94.55	mg/dL	40 - 200	
VLDL <i>Calculated</i>	18.91	mg/dL	10 - 40	
Chol/HDL <i>Calculated</i>	3.54		0 - 4.1	
LDL Cholesterol <i>Calculated</i>	97.82	mg/dL	0.00 - 100.00	

NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP

LDL CHOLESTEROL	CHOLESTEROL	HDL CHOLESTEROL	TRIGLYCERIDES
Optimal <100	Desirable <200	Low <40	Normal <150
Near Optimal 100-129	Border Line 200-239	High >60	Border High 150-199
Borderline 130-159	High >240	-	High 200-499
High 160-189	-	-	-

- LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment
- For LDL Cholesterol level Please consider direct LDL value
Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.
- Detail test interpreation available from the lab
- All tests are done according to NCEP guidelines and with FDA approved kits.
- LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Page 5 of 9

Printed On : 06-May-2024 17:16



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Serum	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 09:57	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Liver Function Test

S.G.P.T. <i>IFCC</i>	19.28	U/L	0 - 59	
S.G.O.T. <i>IFCC</i>	15.91	U/L	15 - 37	
Alkaline Phosphatase <i>Modified IFCC method</i>	98.43	U/L	40 - 150	
Proteins (Total) <i>Biuret</i>	7.05	g/dL	6.4 - 8.2	
Albumin <i>Bromo Cresol Green</i>	4.33	g/dL	3.4 - 5.0	
Globulin <i>Calculated</i>	2.72	gm/dL	2 - 4.1	
A/G Ratio <i>Calculated</i>	1.6		1.0 - 2.1	
Bilirubin Total <i>Diazotized Sulfanilic Acid Method</i>	0.26	mg/dL	0.2 - 1.0	
Bilirubin Conjugated <i>Diazotized Sulfanilic Acid Method</i>	0.12	mg/dL		
Bilirubin Unconjugated <i>Calculated</i>	0.14	mg/dL	0 - 0.8	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Page 6 of 9

Printed On : 06-May-2024 17:16



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Serum	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 10:28	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BIOCHEMICAL INVESTIGATIONS

Thyroid Function Test

Triiodothyronine (T3) <i>ECLIA</i>	1.43	ng/mL	0.70 - 2.04	
Thyroxine (T4) <i>ECLIA</i>	8.25	µg/dL	5.5 - 11.0	
TSH <i>ECLIA</i>	3.960	µIU/mL	0.40 - 4.20	

INTERPRETATIONS

Useful for Monitoring patients on thyroid replacement therapy, Confirmation of thyroid-stimulating hormone (TSH) suppression in thyroid cancer patients on thyroxine therapy, for Prediction of thyrotropin-releasing hormone-stimulated TSH response, as An aid in the diagnosis of primary hyperthyroidism, for Differential diagnosis of hypothyroidism.
The ability to quantitate circulating levels of thyroid-stimulating hormone (TSH) is important in evaluating thyroid function. It is especially useful in the differential diagnosis of primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low or normal. Concentrations of 5.1 mIU/ml to 7.0 mIU/ml are considered borderline hypothyroid

CAUTIONS

Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

TSH ref range in Pregnancy	Reference range (microu/ml)
First trimester	0.24 - 2.00
Second trimester	0.43-2.2
Third trimester	0.8-2.5

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Page 7 of 9

Printed On : 06-May-2024 17:16



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Spot Urine	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 10:50	Acc. Remarks :	Ref Id2 :

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
URINE EXAMINATION (STRIP METHOD AND FLOWCYTOMETRY)				

Physical examination

Colour Pale yellow
Transparency Clear

Chemical Examination By Sysmex UC-3500

Sp.Gravity	1.025		1.003 - 1.035
pH	6.0		4.6 - 8
Leucocytes (ESTERASE)	Negative		Negative
Protein	Negative		Negative
Glucose	Negative		Negative
Ketone Bodies Urine	Negative		Negative
Urobilinogen	Negative		Negative
Bilirubin	Negative		Negative
Blood	Negative		Negative
Nitrite	Negative		Negative

Flowcytometric Examination By Sysmex UF-5000

Leucocyte	Nil	/HPF	Nil
Red Blood Cell	Nil	/HPF	Nil
Epithelial Cell	3-5	/HPF	Present(+)
Bacteria	Nil	/µL	Nil
Yeast	Nil	/µL	Nil
Cast	Nil	/HPF	Nil
Crystals	Nil	/HPF	Nil

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
 Consultant Pathologist



LABORATORY REPORT



Name : Mrs KALPNABEN B VASAVA	Sex/Age : Female / 35 Years	Case ID : 40308001493
Ref. By : Mediwheel Full Body Health Checkup	Dis. At :	Pt. ID :
Bill. Loc. : Health packages		Pt. Loc. :
Reg Date and Time : 30-Mar-2024 07:57	Sample Type : Spot Urine	Mobile No. :
Sample Date and Time : 30-Mar-2024 07:57	Sample Coll. By : non	Ref Id1 :
Report Date and Time : 30-Mar-2024 10:50	Acc. Remarks :	Ref Id2 :

Parameter	Unit	Expected value	Result/Notations				
			Trace	+	++	+++	++++
pH	-	4.6-8.0					
SG	-	1.003-1.035					
Protein	mg/dL	Negative (<10)	10	25	75	150	500
Glucose	mg/dL	Negative (<30)	30	50	100	300	1000
Bilirubin	mg/dL	Negative (0.2)	0.2	1	3	6	-
Ketone	mg/dL	Negative (<5)	5	15	50	150	-
Urobilinogen	mg/dL	Negative (<1)	1	4	8	12	-

Parameter	Unit	Expected value	Result/Notifications				
			Trace	+	++	+++	++++
Leukocytes (Strip)	/micro L	Negative (<10)	10	25	100	500	-
Nitrite(Strip)	-	Negative	-	-	-	-	-
Erythrocytes(Strip)	/micro L	Negative (<5)	10	25	50	150	250
Pus cells (Microscopic)	/hpf	<5	-	-	-	-	-
Red blood cells(Microscopic)	/hpf	<2	-	-	-	-	-
Cast (Microscopic)	/lpf	<2	-	-	-	-	-

Pending Services
Stool Examination

----- End Of Report -----

For test performed on specimens received or collected from non-NSRL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. NSRL will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shweta Patel
Consultant Pathologist

Printed On : 06-May-2024 17:16